Abiraterone News and Research

RSS
Two new treatments may benefit patients with high risk prostate cancer, trial shows

Two new treatments may benefit patients with high risk prostate cancer, trial shows

New blood test can predict drug resistance in patients with advanced prostate cancer

New blood test can predict drug resistance in patients with advanced prostate cancer

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

Molecular mechanism reprograms tumor cells to drive treatment resistance in advanced prostate cancer

Molecular mechanism reprograms tumor cells to drive treatment resistance in advanced prostate cancer

Taking prostate cancer drug with low-fat breakfast can be effective and less expensive, study finds

Taking prostate cancer drug with low-fat breakfast can be effective and less expensive, study finds

Duke researchers discover blood markers linked to drug-resistant tumor cells

Duke researchers discover blood markers linked to drug-resistant tumor cells

Novel way of hitting prostate cancer

Novel way of hitting prostate cancer

Genomic profiling could help provide targeted therapies for difficult to treat cancer tumors

Genomic profiling could help provide targeted therapies for difficult to treat cancer tumors

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

Moffitt researchers develop novel therapeutic strategy to keep resistant cells in check

Moffitt researchers develop novel therapeutic strategy to keep resistant cells in check

New clinical trial launched to test potential drug that could help immune system combat cancer

New clinical trial launched to test potential drug that could help immune system combat cancer

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

ESSA reports net loss of $11.5 million for year ended September 30, 2015

ESSA reports net loss of $11.5 million for year ended September 30, 2015

New drug combination shows promise in treating men with metastatic prostate cancer

New drug combination shows promise in treating men with metastatic prostate cancer

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Mylan sued in connection with ANDA filing for generic version of Zytiga

Mylan sued in connection with ANDA filing for generic version of Zytiga

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

ESSA Pharma reports net loss of $5.9 million for second quarter 2015

ESSA Pharma reports net loss of $5.9 million for second quarter 2015

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC